News

Check out new data from phase 3 study of Ingrezza for the real-world management of tardive dyskinesia.

A recent study analyzed longitudinal data of patients with schizophrenia or major depressive disorder to rank treatment regimens in terms of weight gain, adverse effects, and response to treatment.

Embracing movement as theory.

An expert shares some clinical pearls from his lecture at the recent American Psychiatric Association Annual Meeting.

The company has announced plans to submit the NDA in the first half of 2025.

“The findings emphasize the importance of monitoring the use of psychotropic combinations, particularly among vulnerable populations.”

Be curious and well-informed about upcoming digital tools in mental health.

A year of unusual graduations…

In this 2-part series, a psychiatrist explores the connections between hostage films and psychiatry.

The latest in mood disorder news, all in one place.

Concierge psychiatry: a type of mental health care delivery through a personalized and high-touch approach.

Here are highlights from the week in Psychiatric Times.

Understanding the heterogeneity and complexities of the histamine monoamine system.

What is new in research on postpartum depression?

The study sheds light on the potential risks and adverse effects of polypharmacy in patients with complex psychiatric conditions.

"The shepherds' swains shall dance and sing, For thy delight each May morning. If these delights thy mind may move, Then live with me and be my Love."

Mental Health Awareness Month may seem redundant in psychiatry. Here's what Psychiatric Times is doing in honor of this month.

Here's everything you need to know about about the 2024 APA Annual Meeting and how to prep for next year's meeting, from members of the Scientific Program Committee.

May is Jewish, Haitian, and Asian Pacific American Heritage Month. What trauma have these groups inherited?

Exploring the connection between motherhood and mental health.

Here's a look at the characteristic methods of communication among patients with BPD.

Eisai and Biogen announced they have initiated a rolling submission for subcutaneous Leqembi for Alzheimer disease.

Experience is an end in itself, not measured in time or goals.

Celebrating the life and smile of Herbert Pardes, MD.

Learning to use a psychedelic agent can be challenging when the protocols are not defined. Here’s how a psychiatrist got started.

Remembering the many ways Carl I. Cohen, MD, added to the field of psychiatry.

Here’s a look at our recent coverage of these disorders in honor of Mother’s Day 2024.